BioD, LLC — a Memphis-based biotechnology company engaged in the development and commercialization of novel biologic products derived from human placental tissues — is pleased to announce it has received its first patent for one of its platform tissue technologies. On January 13, 2015, the U.S. Patent and Trademark Office issued U.S. Patent Number 8,932,805, “Birth Tissue Material and Method of Preparation.” The patent covers the company’s BioDFactor® Viable Tissue Matrix product family, a cryopreserved allograft product derived from human placental tissues that is used as a wound covering in the treatment of localized tissue defects or areas of inflammation.
Placental tissues, including the amniotic lining of the placenta, have been used in wound dressings for over 100 years. Allografts made from placental tissues provide innate characteristics that are well recognized by the medical community: they rarely trigger an immune response in the recipient; are anti-inflammatory, anti-microbial and anti-adhesive; and provide a unique matrix that may support growth of new cells for improved healing. BioD’s new patent covers the company’s unique method of processing placental tissues to create cryopreserved tissue allografts that preserve these innate characteristics in a form that physicians can easily utilize for localized tissue repair and reconstruction.
Timothy Brahm, BioD Founder, Chairman of the Board and Chief Development Officer, says, “We are pleased the patent office has recognized the novel aspects of our methods to preserve the innate regenerative properties of placental tissues. Gaining patent protection for our tissue processing method not only validates and reinforces the unique and valuable nature of this invention, but also protects the value of our company’s intellectual property and our unique portfolio of placental-derived allograft products.”
BioD’s allografts provide a natural alternative to synthetic, cadaveric or animal derived regenerative products and may be used in a broad range of clinical applications, including the treatment of complex chronic wounds, acute wounds such as decubitus or pressure ulcers, or localized areas of injury or inflammation; filling of soft tissue defects or voids, and postoperative wound care.
Brahm says, “BioD is committed to developing innovative solutions for the medical community that will improve patient care and reduce healthcare costs. We have filed over 30 patent applications connected to our unique processes and products, and the patent received for our BioDFactor line is a significant milestone in the growth of the company.”
BioD, LLC, is a vertically integrated biotechnology company engaged in the development and commercialization of novel biologic products derived from the placental tissues. Our research and development efforts are focused on the regenerative potential of amnion and the other placental tissues, which offer a unique biologic structure, a rich source of undifferentiated stem cells, and a unique immune privilege that characterizes their function in the body. From the recovery of tissue from live, healthy donors during childbirth to the development of new products that improve patient outcomes, BioD is unlocking the regenerative potential of the human body. For more information, visit www.biodlogics.com.
Contact: Darin Gerlach Vice President, Marketing 901-417-7868